Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Feb 1;27(2):112-117.
doi: 10.1097/SPV.0000000000000749.

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial

Kimberly L Ferrante  1 , Erika J Wasenda  2 , Carrie E Jung  2 , Emily R Adams-Piper  3 , Emily S Lukacz  2
Affiliations
Randomized Controlled Trial

Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women: A Randomized Clinical Trial

Kimberly L Ferrante et al. Female Pelvic Med Reconstr Surg. .

Abstract

Objectives: We aimed to compare the efficacy of 2 commonly used contemporary vaginal estrogen administrations versus placebo for the prevention of urinary tract infection (UTI) in postmenopausal women with a clinical diagnosis of recurrent UTI (rUTI).

Methods: This was an investigator-initiated, multicenter, single-blind, randomized, placebo-controlled trial of vaginal estrogen (delivered via ring or cream) compared with placebo. Postmenopausal women with documented rUTI were randomized to receive either vaginal estrogen (via ring or cream) or placebo cream in a 1:1:1 fashion. The primary outcome was occurrence of UTI at 6 months. After 6 months, open-label use of ring or active cream was offered to all participants for an additional 6 months. Because of slower than expected recruitment, sample size calculations and block randomization schema were revised to combine estrogen groups (ring or cream) for statistical comparisons to placebo cream in a 1:1 fashion.

Results: Thirty-five women were randomized with 9 dropouts (1 ring, 2 cream, and 6 placebo) prior to the 6 months. Intention-to-treat analysis (assuming dropouts as failures) revealed fewer women treated with vaginal estrogen had a UTI within 6 months versus placebo (11/18 vs 16/17, respectively; P = 0.041). Per-protocol analysis revealed fewer subjects treated with vaginal estrogen had a UTI at 6 months (8/15 vs 10/11, respectively; P = 0.036).

Conclusions: Commonly prescribed forms of vaginal estrogen with contemporary dosing schedules prevent UTIs in postmenopausal women with an active diagnosis of rUTI.

Trial registration: ClinicalTrials.gov NCT01958073.

PubMed Disclaimer

References

    1. Bermingham SL, Ashe JF. Systematic review of the impact of urinary tract infections on health-related quality of life. BJU Int 2012;110(11c):E830–E836.
    1. Raz R. Urinary tract infection in postmenopausal women. Korean J Urol 2011;52(12):801–808.
    1. Walters MD, Karram MM. Urogynecology and Reconstructive Pelvic Surgery. Philidelphia, PA: Mosby Elsevier; 2007.
    1. Raz R, Colodner R, Rohana Y, et al. Effectiveness of estriol-containing vaginal pessaries and nitrofurantoin macrocrystal therapy in the prevention of recurrent urinary tract infection in postmenopausal women. Clin Infect Dis 2003;36(11):1362–1368.
    1. Mody L, Juthani-Mehta M. Urinary tract infections in older women. JAMA 2014;311(8):844.

Publication types

Associated data